ReviewDrug design, development and therapy2016

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod.

Jorge Correale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.